Bruton’s Tyrosine Kinase (BTK) inhibitors have become an important part of treatment in patients with Chronic Lymphocytic Leukaemia and B-Cell Lymphomas including Mantle Cell Lymphoma and Waldenstrom’s Macroglobulineamia.
Professor Chan Cheah discusses early results of the large phase I LOXO-305 (BRUIN) trial which evaluates a non-covalent reversible BTK inhibitor LOXO-305 in patients with previously treated B-cell malignancies. Overall, LOXO-305 has a good safety profile with few severe adverse events and a favourable side-effect profile relative to first generation BTK inhibitors. Furthermore, activity was observed across a range of b-cell malignancies where BTK inhibition was expected to be successful including amongst patients who experienced treatment failure due to intolerance and resistance to first generation BTK inhibitors.